1.Wesohules, DJ, McMath, JA, Gallagher, Ret al.Methadone and the hospice patient: prescribing trends in the home-care setting. Pain Med 2003; 4: 269–76.
2.Niveau, G, Rougemont, AL, La Harpe, R. Methadone Maintenance treatment, criminality and overdose – related deaths. An ecological study, 1983 – 1999. Eur J Public Health 2002; 12: 224–7.
3.McCaffrey, BR. Methadone treatment: our vision for the future. J Addict Dis. 2001; 20:93–101
4.Stitcherling, C, Schaer, B, Ammann, Pet al, Methadone-induced Torsades de Pointes tachycardias. Swiss Med Weekly 2005 135: 282–285.
5.European Agency for the evaluation of Medicinal Products, EMEA public statement to suspend the marketing authorization for Orlaam (levacetylmethadol) in the European Union. 04 19 2001.
6.Deamer, RL, Nllson, DR, Clark, DSet al.Torsades de Pointes associated with high dose levomethadyl acetate (ORLAAM) J Addict Dos 2001; 20: 7–14
Stitcherling, C, Schaer, B, Ammann, Pet al, Methadone -induced Torsades de Pointes tachycardias. Swiss Med Weekly 2005 135: 282–285.
7.Gupta, A, Lawrence, A, Krishnan, Ket al, Current Concepts in the mechanism and management of drug-induced QT prolongation and Torsades de Pointes. American Heart Journal, 06 2007 153(6): 891–899.
8.Martell, BAet al, Impact of methadone treatment on cardiac repolarisation and conduction in opioid users. Am J cardiol 2005; 95: 915–918
9.Krantz, MJ, Lewkowiez, L, Hays, Het al.Torsades depointes associated with very high dose methadone. Ann Intern Med 2002; 137: 501–4
10.Whret, G, Voide, C, Gex-Fabry, Met al.Drug Induced Long QT Syndrome in Injection drug users receiving Methadone. Arch Intern Med 2006:166: 1280–1287
11.Fanoe, S, Huidt, C, Ege, Pet al, Syncope and QT prolongation among patients treated with methadone for heroin dependence in the City of Copenhagen. Heart 2007 09; 93(9) 1051–5
12.Lamont, P, Hunt, S, A twist on Torsade: A Prolonged QT interval on Methadone. J Gen Intern Med 206, 11 21 (11), C9–C12